Abstract:Objective To assess the improvement of prostate cancer detection rate ( PCDR) with the advance of prostate biopsy technologies and analyse the changing epidemiology of patients with positive prostate biopsy, especially the PCDR and classficaton of risk.Methods From March 1999 to March 2015, a total of 3 762 patients were recruited to the department of urology, the first affiliated hospital of Nanjing medical university.All patients underwent a systematic 6-, 8-or 13-core biopsy, guided by finger or TRUS. The PCDR of different prostate specific antigen ( PSA) interval was analyzed.The PCDR of 6-or 8-core biopsy guided by finger and 13-core biopsy guided by TRUS were compared.The trends of PSA level, age and Gleason score in the patients with positive biopsy were summarized.Results A total of 3 762 patients underwent prostate biopsies and PCa were detected in 1479 patients (39.3%).Finger-guided 6-core biopsy was performed on 1 106 patients, and PCa were detected in 343 cases ( 31.0%) .Finger-guided 8-core biopsy was performed on 398 patients, and PCa were diagnosed in 144 cases (36.2%).Since 2009, 2 258 patients underwent TRUS-guided 13-core biopsy, and 992 ( 43.9%) were diagnosed as PCa, higher than that of finger-guided biopsies ( 43.9% vs.32.4%, P<0.001 ) .The PCDR ( 37.8% vs.57.6%, P<0.001) and mean Gleason score (6.88 vs.7.14, P<0.001) of patients with abnormal PSA level (>4 ng/ml) were lower than that of positive in digital rectal examination.The PCDR of 6 needles biopsy was higher in prostate peripheral zone than that of prostate medial zone (37.5% vs.31.4%, P<0.001) and further analysis indicated that the PCDR of extra 13th biopsy of the area with abnormal TRUS or MRI findings was higher than the mean positive rate of the other 12 biopsies.Regarding adverse effects, 34.9%(1312/3762) reported slight gross hematuria or microscopic haematuria, 56 ( 1.5%) developed gross hematuria, 72 (1.9%) occurred rectal bleeding, 63(1.7%) needed short-term hospitalization due to fever, one patient suffered hepatorenal function failure and one patient died after biopsy.Since 1999, the PSDR rise gradually. With the increase of tPSA level, Gleason score increased in biopsy positive patients.The percentage of low risk PCa patients increased from 6.5% to 15.7% gradually in last decade, while the percentage of intermediate or high risk PCa patients is still over 80%.Since 2009, the percentage of patients who underwent prostate biopsies because of evaluated PSA level was higher than before ( 46.7% vs.34.1%, P<0.001).The PCDR of patients with an evaluated tPSA level showed no difference compared with the patients presented lower urinary tract symptoms ( LUTS ) ( 45.2% vs.43.2%, P =0.362 ) , while their mean Gleason score in positive patients was lower than that of LUTS group(6.76 vs.7.25,P<0.001). Conclusions The PCDR of TRUS-guided 13-core transrectal prostate biopsy was significantly higher than that of finger-guided 6-or 8-core biopsy.Due to the application of PSA test, the PCDR increased gradually and the mean age of positive patients decreased.The higher the age, the higher the PCDR.Gleason score was higher when patients with positive DRE, compared to an evaluated tPSA level.Biopsies of prostate peripheral zone is helpful to improve the PCDR.The higher the tPSA level, the higher the Gleason score. With the application of PSA test, TRUS-guided 13-core prostate biopsy detected more low risk PCa, and most of PCa were still clinical significant.

Analysis of clinical features of 331 cases of prostate biopsy in single center

Multivariate study of factors affecting the results of prostate biopsy in PSA grey zone

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

Transrectal prostate biopsy:a review of 16 years experience in single center

Clinical Significance of Prostate Biopsy in Patients with Serum High -Sensitivity C -Reactive Protein Meas-Urement

Clinical analysis of transrectal ultrasound guided needle biopsies of the prostate in 540 patients

Prostate Biopsy Results and Clinicopathological Characteristics of the 55 Years or Younger Patients

Clinicopathologic analysis of prostate biopsy in men younger than 50 years of age with prostate-specific antigen 4-10 μg/L

Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011.

Transrectal Ultrasounography Guided Prostate Biopsy and Its Influencing Factors

Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?

Clinical Effect Study of Serum PSA Level and Digital Rectal Examination in Guiding the Prostate Biopsy

Clinical analysis of transrectal ultrasound prostate biopsy (reports of 38 cases)

Clinical analysis of 82 patients with elevated serum PSA whose needle biopsies of the prostate showed negative results

Analysis of spatial distribution characteristics and clinical related factors of positive sites of prostate puncture

The Clinical Analysis of Transrectal Ultrasound Prostate Biopsy

Comprehension of Prostate Puncture Biopsy by Transrectal Ultrasound (report of 658 Cases)

Ratio of initial prostate specific antigen to free prostate specific antigen on diagnosis of prostate carcinoma in Chinese men during post-prostate specific antigen era

Clinical significance of ultrasound-guided systematic biopsy in pati ents with prostate cancer

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml